<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915538</url>
  </required_header>
  <id_info>
    <org_study_id>WSMR 2008-2</org_study_id>
    <nct_id>NCT00915538</nct_id>
  </id_info>
  <brief_title>Comparing Bronchodilation of Symbicort With and With Out Valved Holding Chamber (Aerochamber Plus)</brief_title>
  <acronym>WSMR2</acronym>
  <official_title>A Comparison of the Bronchodilating Activity of Symbicort pMDI 160/4.5 Used in the Conventional Manner and With a Valved Spacer Holding Chamber (Aerochamber Plus)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Sky Medical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Western Sky Medical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the amount of bronchial tube relaxation from the formoterol medicine
      contained in the symbicort pMeterd Dose Inhaler( a combination of budesonide ,a steroid, and
      formoterol, a drug which relaxes the bronchial smooth muscle. The comparison will be using
      the pMDI in the usual fashion to the pMDIs and a spacer which allows more time for breathing
      in the medication. Breathing tests will be measured over a 12 hour period for the comparison.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12 hour AUC of FEV-1</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in FEV-1/FVC</measure>
    <time_frame>12 hour</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Conventional First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will use pMDI in usual fashion first and cross over to pMDI and valved holding chamber</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spacer First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive pMDI and Valved holding chamber on fist day. On anther day will receive pMDI in usual fashion. Pulmonary functions wil be measured over 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pMD Symbicort 160/4.5</intervention_name>
    <description>The subjects will receive Symbicort pMDI 160/4.5 pMDI used in conventional fashion, and have pulmonary function measured over 12 hours. Secondly on another day, they will receive pMDI using a valved holding chamber</description>
    <arm_group_label>Conventional First</arm_group_label>
    <other_name>Symbicort</other_name>
    <other_name>Aerochamber plus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort</intervention_name>
    <description>Symbicort 160/4.5 will be administered first first through a valved holding chamber, and on another day in the conventional fashion. Pulmonary functions will be measured ove r12 hours</description>
    <arm_group_label>Spacer First</arm_group_label>
    <other_name>Aerochamber plus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asthma with 15% or more increase in FEV-1 after 180-260 mcg of albuterol pMDI

        Exclusion Criteria:

          -  Any illness or condition which might place subject at risk in the study;e.g. some
             cardiovascular disorders Inability to understand and sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Catherine Posey, CCRC</last_name>
    <phone>915-544-2557</phone>
    <email>catposey@westernskymed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lyndon E Mansfield, MD CPI</last_name>
    <phone>915-544-2557</phone>
    <email>immunman@westernskymed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Western Sky Medical Research</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Posey, CCRC</last_name>
      <phone>915-544-2557</phone>
      <email>catposey@westernskymed.com</email>
    </contact>
    <contact_backup>
      <last_name>Lyndon E Mansfield, MD CPI</last_name>
      <phone>915-544-2557</phone>
      <email>immunman@westernskymed.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lyndon E Mansfield, MD CPI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2009</study_first_posted>
  <last_update_submitted>June 5, 2009</last_update_submitted>
  <last_update_submitted_qc>June 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>Lyndon E. Mansfield</name_title>
    <organization>Western Sky Medical Research</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Formoterol</keyword>
  <keyword>LABA</keyword>
  <keyword>Symbicort</keyword>
  <keyword>Aerochamber</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 23, 2010</submitted>
    <returned>October 19, 2010</returned>
    <submitted>June 27, 2012</submitted>
    <returned>August 3, 2012</returned>
    <submitted>December 16, 2013</submitted>
    <returned>February 7, 2014</returned>
    <submitted>December 15, 2015</submitted>
    <returned>January 21, 2016</returned>
    <submitted>February 3, 2016</submitted>
    <returned>March 2, 2016</returned>
    <submitted>April 6, 2017</submitted>
    <returned>April 27, 2017</returned>
    <submitted>May 8, 2017</submitted>
    <returned>June 9, 2017</returned>
    <submitted>January 10, 2018</submitted>
    <returned>February 9, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

